UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 23, 2007
ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)
|
Massachusetts |
|
0-17999 |
|
04-2726691 |
|
(State or other jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
incorporation) |
|
|
|
|
|
128 Sidney Street, Cambridge, MA 02139 |
|
(Address of principal executive offices) (Zip Code) |
|
|
|
Registrant’s telephone number, including area code: (617) 995-2500 |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02. – DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
(a) Not applicable.
(b) On July 26, 2007, ImmunoGen, Inc. (Nasdaq: IMGN) announced the July 23, 2007 resignation from the Company of Pauline Jen Ryan, formerly the Senior Vice President, Corporate Development and Operations.
A copy of the press release regarding Ms. Ryan’s departure is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(c), (d), and (e) Not applicable.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
|
Exhibit No. |
|
Exhibit |
|
99.1 |
|
Press Release of ImmunoGen, Inc. dated July 26, 2007 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ImmunoGen, Inc. |
|
|
|
|
|
(Registrant) |
|
|
|
|
|
|
|
Date: July 26, 2007 |
|
/s/ Daniel M. Junius |
|
|
|
|
Daniel M. Junius |
|
|
|
|
Executive Vice President and Chief Financial Officer |
|
3
EXHIBIT INDEX
|
Exhibit No. |
|
Exhibit |
|
99.1 |
|
Press Release of ImmunoGen, Inc. dated July 26, 2007 |
4
Exhibit 99.1
|
128 Sidney Street, Cambridge, MA 02139-4239 |
|
TEL: (617) 995-2500 FAX: (617) 995-2510 |
Contacts:
|
Investors |
Media: |
|
Carol Hausner |
Kathryn Morris |
|
Executive Director, Investor Relations |
KMorrisPR |
|
and Corporate Communications |
(845) 635-9828 |
|
ImmunoGen, Inc. |
Kathryn@kmorrispr.com |
|
(617) 995-2500 |
|
|
info@immunogen.com |
|
For Immediate Release
ImmunoGen, Inc. Announces Departure of Pauline Jen Ryan
CAMBRIDGE, MA, July 26, 2007 – ImmunoGen, Inc. (Nasdaq: IMGN) today announced that Pauline Jen Ryan has resigned from the Company to pursue other interests. Ms. Ryan was most recently Senior Vice President, Corporate Development and Operations at ImmunoGen.
“We are deeply grateful to Pauline for her distinguished service to the Company over the past eight years,” stated Mitchel Sayare, Chairman and CEO. “Pauline’s contributions helped provide us with a solid framework for growth as we go forward, and we wish her the very best in her future endeavors.”
The Company has initiated a search to replace Ms. Ryan. In the interim, her day-to-day responsibilities will be handled by other members of the Company’s senior management team.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company’s proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing – huN901-DM1 and huC242-DM4. Three anticancer compounds are in clinical testing through ImmunoGen’s collaborations with other companies – AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-DM1, in development by Genentech. Multiple compounds are in research/preclinical development.
# # #